One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™
Completed
- Conditions
- Type 1 Diabetes Mellitus
- Registration Number
- NCT02939118
- Lead Sponsor
- ViaCyte
- Brief Summary
The purpose of this trial is to evaluate the long-term safety in subjects previously implanted with VC-01™ combination product.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 51
Inclusion Criteria
- Previous implantation of VC-01™ combination product with subsequent explantation of all VC-01 units.
Exclusion Criteria
- There are no exclusion criteria for this trial.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of adverse events reported during the study. 12 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the long-term safety outcomes of VC-01™ in Type 1 Diabetes Mellitus patients over one year post-implantation?
How does VC-01™ combination product compare to standard-of-care in managing blood glucose levels for Type 1 Diabetes?
What biomarkers are used to predict patient response to VC-01™ in clinical trials for Type 1 Diabetes Mellitus?
What adverse events have been reported with VC-01™ implants and what are the recommended management strategies?
Are there any alternative cell therapy approaches to VC-01™ for Type 1 Diabetes Mellitus and how do they differ?